31 August 2017Big Pharma

Video interview: Predicting Brexit’s life sciences impact

The practical implications of Brexit, including on the Unified Patent Court (UPC), were the focus of a roundtable discussion at Life Sciences Patent Network North America, an industry event.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Video interview: Regulatory issues key for life sciences in Brexit debate

25 August 2017 With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Video interview: Novartis discusses challenges around second medical use

23 August 2017 The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.

More on this story

Video interview: Regulatory issues key for life sciences in Brexit debate

25 August 2017 With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Video interview: Novartis discusses challenges around second medical use

23 August 2017 The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.

More on this story

Video interview: Regulatory issues key for life sciences in Brexit debate

25 August 2017 With Brexit negotiations well under way, Nicola Dagg, global head of IP at Allen & Overy, says ensuring that all of the regulatory and compliance requirements are in place immediately after Britain leaves the EU is the most important aspect of negotiations for the life sciences.

Video interview: Novartis discusses challenges around second medical use

23 August 2017 The biggest challenges in the life sciences concern second medical use patents and incentives for innovation, according to Lydia McNally, vice president, head of patents, oncology at Novartis.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice